JMJD6分子在肿瘤发生发展中的作用的研究进展
Research Progress on the Role of JMJD6 Molecule in Tumorigenesis and Tumor Development
DOI: 10.12677/acm.2024.14102775, PDF,    国家自然科学基金支持
作者: 张宏鑫*：华北理工大学临床医学院，河北 唐山；刘 岩：华北理工大学生命科学学院，河北 唐山；张景华#：华北理工大学临床医学院，河北 唐山；唐山市妇幼保健院乳腺外科，河北 唐山
关键词: JMJD6蛋白；肿瘤；靶向治疗；JMJD6 Protein； Tumor； Targeted Therapy
摘要: 含Jumonji C结构域蛋白6 (Jumonji C-domain containing protein 6, JMJD6)是Fe(Ⅱ)和α-酮戊二酸依赖性的加氧酶，它具有催化mRNA前体片段中蛋白赖氨酸残基羟化的作用。近年来，关于JMJD6在肿瘤的发生、发展及转移中的作用逐渐被揭示。JMJD6不仅能通过其酶活性影响肿瘤细胞的表观遗传状态，还能通过与其他分子如核受体、转录因子等互作，调节肿瘤相关基因的表达。研究表明，JMJD6与多种肿瘤类型如乳腺癌、肺癌和前列腺癌等的发生密切相关。此外，JMJD6的活性与肿瘤患者的预后及药物敏感性相关，使其成为潜在的治疗靶点。目前，针对JMJD6的临床研究正在探索其作为生物标志物及治疗靶点的潜力，例如在抗肿瘤药物开发中的应用。本文旨在综述JMJD6的调控机制和临床研究进展，为未来的研究方向及临床应用提供理论基础。
Abstract: Jumonji C-domain containing protein 6 (JMJD6) is a Fe(II) and α-ketoglutarate-dependent dioxygenase that catalyzes the hydroxylation of lysine residues in precursor mRNA fragments. In recent years, the role of JMJD6 in tumorigenesis, development, and metastasis has been gradually elucidated. JMJD6 not only influences the epigenetic state of tumor cells through its enzymatic activity, but also regulates the expression of tumor-related genes by interacting with other molecules, such as nuclear receptors and transcription factors. Studies have shown that JMJD6 is closely associated with the occurrence of various types of tumors, such as breast cancer, lung cancer, and prostate cancer. Furthermore, the activity of JMJD6 is related to the prognosis and drug sensitivity of cancer patients, making it a potential therapeutic target. Currently, clinical studies on JMJD6 are exploring its potential as a biomarker and therapeutic target, for example, in the application of the development of anti-tumor drugs. This paper aims to review the regulatory mechanisms and clinical research progress of JMJD6, providing a theoretical basis for future research directions and clinical applications.
文章引用：张宏鑫, 刘岩, 张景华. JMJD6分子在肿瘤发生发展中的作用的研究进展[J]. 临床医学进展, 2024, 14(10): 1120-1129. https://doi.org/10.12677/acm.2024.14102775

参考文献

[1] Yang, J., Chen, S., Yang, Y., Ma, X., Shao, B., Yang, S., et al. (2020) Jumonji Domain‐Containing Protein 6 Protein and Its Role in Cancer. Cell Proliferation, 53, e12747. [Google Scholar] [CrossRef] [PubMed]
[2] Cockman, M.E., Sugimoto, Y., Pegg, H.B., Masson, N., Salah, E., Tumber, A., et al. (2022) Widespread Hydroxylation of Unstructured Lysine-Rich Protein Domains by JMJD6. Proceedings of the National Academy of Sciences of the United States of America, 119, e2201483119. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, K., Yang, C., Li, H., Liu, X., Zheng, M., Xuan, Z., et al. (2022) Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response. Frontiers in Immunology, 13, Article 859893. [Google Scholar] [CrossRef] [PubMed]
[4] Pedersen, M.T. and Helin, K. (2010) Histone Demethylases in Development and Disease. Trends in Cell Biology, 20, 662-671. [Google Scholar] [CrossRef] [PubMed]
[5] Kwok, J., O’Shea, M., Hume, D.A. and Lengeling, A. (2017) JMJD6, a JMJC Dioxygenase with Many Interaction Partners and Pleiotropic Functions. Frontiers in Genetics, 8, Article 32. [Google Scholar] [CrossRef] [PubMed]
[6] Liu, Y., Long, Y., Wang, S., Zhang, Y., Li, Y., Mi, J., et al. (2018) JMJD6 Regulates Histone H2A.X Phosphorylation and Promotes Autophagy in Triple-Negative Breast Cancer Cells via a Novel Tyrosine Kinase Activity. Oncogene, 38, 980-997. [Google Scholar] [CrossRef] [PubMed]
[7] Zhou, D.X., Zhou, D., Zhan, S.Q., Wang, P., Qin, K., Gan, W., et al. (2017) Inhibition of JMJD6 Expression Reduces the Proliferation, Migration and Invasion of Neuroglioma Stem Cells. Neoplasma, 64, 700-708. [Google Scholar] [CrossRef] [PubMed]
[8] Poulard, C., Rambaud, J., Lavergne, E., Jacquemetton, J., Renoir, J., Trédan, O., et al. (2015) Role of JMJD6 in Breast Tumourigenesis. PLOS ONE, 10, e0126181. [Google Scholar] [CrossRef] [PubMed]
[9] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[10] Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M.H., Moradi-Kalbolandi, S., et al. (2020) Breast Cancer: Biology, Biomarkers, and Treatments. International Immunopharmacology, 84, Article ID: 106535. [Google Scholar] [CrossRef] [PubMed]
[11] Lee, Y.F., Miller, L.D., Chan, X.B., Black, M.A., Pang, B., Ong, C.W., et al. (2012) JMJD6 Is a Driver of Cellular Proliferation and Motility and a Marker of Poor Prognosis in Breast Cancer. Breast Cancer Research, 14, Article No. 3001. [Google Scholar] [CrossRef] [PubMed]
[12] Aprelikova, O., Chen, K., El Touny, L.H., Brignatz-Guittard, C., Han, J., Qiu, T., et al. (2016) The Epigenetic Modifier JMJD6 Is Amplified in Mammary Tumors and Cooperates with C-Myc to Enhance Cellular Transformation, Tumor Progression, and Metastasis. Clinical Epigenetics, 8, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[13] Biswas, A., Mukherjee, G., Kondaiah, P. and Desai, K.V. (2020) Both EZH2 and JMJD6 Regulate Cell Cycle Genes in Breast Cancer. BMC Cancer, 20, Article No. 1159. [Google Scholar] [CrossRef] [PubMed]
[14] Cioni, B., Ratti, S., Piva, A., Tripodi, I., Milani, M., Menichetti, F., et al. (2023) JMJD6 Shapes a Pro-Tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer. Molecular Cancer Research, 21, 614-627. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, J., Ni, S., Zhao, W., Dong, X. and Wang, J. (2013) High Expression of JMJD6 Predicts Unfavorable Survival in Lung Adenocarcinoma. Tumor Biology, 34, 2397-2401. [Google Scholar] [CrossRef] [PubMed]
[16] Ge, X., Jiang, Y., Hu, X. and Yu, X. (2021) MicroRNA-106a-5p Alleviated the Resistance of Cisplatin in Lung Cancer Cells by Targeting Jumonji Domain Containing 6. Transplant Immunology, 69, Article ID: 101478. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, Z., Yang, Y. and Zhang, X. (2017) MiR-770 Inhibits Tumorigenesis and EMT by Targeting JMJD6 and Regulating WNT/β-Catenin Pathway in Non-Small Cell Lung Cancer. Life Sciences, 188, 163-171. [Google Scholar] [CrossRef] [PubMed]
[18] Yu, X., Jiang, Y., Hu, X. and Ge, X. (2021) LINC00839/miR-519d-3p/JMJD6 Axis Modulated Cell Viability, Apoptosis, Migration and Invasiveness of Lung Cancer Cells. Folia Histochemica et Cytobiologica, 59, 271-281. [Google Scholar] [CrossRef] [PubMed]
[19] Maki, H. and Hasegawa, K. (2022) Advances in the Surgical Treatment of Liver Cancer. BioScience Trends, 16, 178-188. [Google Scholar] [CrossRef] [PubMed]
[20] Wan, J., Liu, H., Yang, L., Ma, L., Liu, J. and Ming, L. (2018) JMJD6 Promotes Hepatocellular Carcinoma Carcinogenesis by Targeting CDK4. International Journal of Cancer, 144, 2489-2500. [Google Scholar] [CrossRef] [PubMed]
[21] Zhao, J., Adams, A., Roberts, B., O’Neil, M., Vittal, A., Schmitt, T., et al. (2018) Protein Arginine Methyl Transferase 1-and Jumonji C Domain‐Containing Protein 6-Dependent Arginine Methylation Regulate Hepatocyte Nuclear Factor 4 Alpha Expression and Hepatocyte Proliferation in Mice. Hepatology, 67, 1109-1126. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, Y., Sui, A., Sun, J., Wu, Y., Liu, F. and Yang, Y. (2023) C‐Jun‐Mediated JMJD6 Restoration Enhances Resistance of Liver Cancer to Radiotherapy through the Il‐4‐Activated ERK Pathway. Cell Biology International, 47, 1392-1405. [Google Scholar] [CrossRef] [PubMed]
[23] Pei, R., Zhao, L., Ding, Y., Su, Z., Li, D., Zhu, S., et al. (2023) JMJD6-BRD4 Complex Stimulates LncRNA HOTAIR Transcription by Binding to the Promoter Region of HOTAIR and Induces Radioresistance in Liver Cancer Stem Cells. Journal of Translational Medicine, 21, Article No. 752. [Google Scholar] [CrossRef] [PubMed]
[24] Kosai-Fujimoto, Y., Itoh, S., Yugawa, K., Fukuhara, T., Okuzaki, D., Toshima, T., et al. (2022) Impact of JMJD6 on Intrahepatic Cholangiocarcinoma. Molecular and Clinical Oncology, 17, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
[25] Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. [Google Scholar] [CrossRef] [PubMed]
[26] Yoshida, K., Hiwasa, T., Ito, M., Ushigome, M., Takizawa, H., Li, S., et al. (2023) Prognostic and Diagnostic Significance of Preoperative Jumonji Domain-Containing 6 Antibodies in Colorectal Cancer. Oncology Letters, 25, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, F., He, L., Huangyang, P., Liang, J., Si, W., Yan, R., et al. (2014) JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of P53 by Hydroxylation. PLOS Biology, 12, e1001819. [Google Scholar] [CrossRef] [PubMed]
[28] Ge, Y., Liu, B., Cui, J. and Li, S. (2019) Livin Promotes Colon Cancer Progression by Regulation of H2A.XY39ph via Jmjd6. Life Sciences, 234, Article ID: 116788. [Google Scholar] [CrossRef] [PubMed]
[29] Motzer, R.J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., et al. (2022) Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 71-90. [Google Scholar] [CrossRef] [PubMed]
[30] Zhang, C., Lu, X., Huang, J., He, H., Chen, L., Liu, Y., et al. (2021) Epigenome Screening Highlights That JMJD6 Confers an Epigenetic Vulnerability and Mediates Sunitinib Sensitivity in Renal Cell Carcinoma. Clinical and Translational Medicine, 11, e328. [Google Scholar] [CrossRef] [PubMed]
[31] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[32] Li, Y., Yu, P., Zou, Y., Cai, W., Sun, W. and Han, N. (2019) Kras-erk Signalling Promotes the Onset and Maintenance of Uveal Melanoma through Regulating JMJD6-Mediated H2A.X Phosphorylation at Tyrosine 39. Artificial Cells, Nanomedicine, and Biotechnology, 47, 4257-4265. [Google Scholar] [CrossRef] [PubMed]
[33] Liu, X., Si, W., Liu, X., He, L., Ren, J., Yang, Z., et al. (2017) JMJD6 Promotes Melanoma Carcinogenesis through Regulation of the Alternative Splicing of PAK1, a Key MAPK Signaling Component. Molecular Cancer, 16, Article No. 175. [Google Scholar] [CrossRef] [PubMed]
[34] Anelli, V., Ordas, A., Kneitz, S., Sagredo, L.M., Gourain, V., Schartl, M., et al. (2018) Ras-Induced miR-146a and 193a Target JMJD6 to Regulate Melanoma Progression. Frontiers in Genetics, 9, Article 675. [Google Scholar] [CrossRef] [PubMed]
[35] Lee, E., Yong, R.L., Paddison, P. and Zhu, J. (2018) Comparison of Glioblastoma (GBM) Molecular Classification Methods. Seminars in Cancer Biology, 53, 201-211. [Google Scholar] [CrossRef] [PubMed]
[36] Rosager, A.M., Dahlrot, R.H., Sørensen, M.D., Bangsø, J.A., Hansen, S. and Kristensen, B.W. (2021) The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. Journal of Neuropathology & Experimental Neurology, 81, 54-60. [Google Scholar] [CrossRef] [PubMed]
[37] Wong, M., Sun, Y., Xi, Z., Milazzo, G., Poulos, R.C., Bartenhagen, C., et al. (2019) JMJD6 Is a Tumorigenic Factor and Therapeutic Target in Neuroblastoma. Nature Communications, 10, Article No. 3319. [Google Scholar] [CrossRef] [PubMed]
[38] Miller, T.E., Liau, B.B., Wallace, L.C., Morton, A.R., Xie, Q., Dixit, D., et al. (2017) Transcription Elongation Factors Represent in Vivo Cancer Dependencies in Glioblastoma. Nature, 547, 355-359. [Google Scholar] [CrossRef] [PubMed]
[39] Northcott, P.A. (2017) Keeping It Real to Kill Glioblastoma. Nature, 547, 291-292. [Google Scholar] [CrossRef] [PubMed]
[40] Wang, J., Lv, N., Lu, X., Yuan, R., Chen, Z. and Yu, J. (2020) Diagnostic and Therapeutic Role of MicroRNAs in Oral Cancer (Review). Oncology Reports, 45, 58-64. [Google Scholar] [CrossRef] [PubMed]
[41] Lee, C., Lee, S.H., Rigas, N.K., Kim, R.H., Kang, M.K., Park, N., et al. (2015) Elevated Expression of JMJD6 Is Associated with Oral Carcinogenesis and Maintains Cancer Stemness Properties. Carcinogenesis, 37, 119-128. [Google Scholar] [CrossRef] [PubMed]
[42] Han, Y., Wang, X., Xia, K. and Su, T. (2021) A Novel Defined Hypoxia-Related Gene Signature to Predict the Prognosis of Oral Squamous Cell Carcinoma. Annals of Translational Medicine, 9, 1565-1565. [Google Scholar] [CrossRef] [PubMed]
[43] Zheng, H., Tie, Y., Fang, Z., Wu, X., Yi, T., Huang, S., et al. (2019) Jumonji Domain-Containing 6 (JMJD6) Identified as a Potential Therapeutic Target in Ovarian Cancer. Signal Transduction and Targeted Therapy, 4, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[44] Tong, D. (2021) The Role of JMJD6/U2AF65/AR-V7 Axis in Castration-Resistant Prostate Cancer Progression. Cancer Cell International, 21, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[45] Paschalis, A., Welti, J., Neeb, A.J., Yuan, W., Figueiredo, I., Pereira, R., et al. (2021) JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Research, 81, 1087-1100. [Google Scholar] [CrossRef] [PubMed]
[46] Cangiano, M., Grudniewska, M., Salji, M.J., Nykter, M., Jenster, G., Urbanucci, A., et al. (2021) Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer. Cancers, 13, Article 2094. [Google Scholar] [CrossRef] [PubMed]
[47] Islam, M.S., Thinnes, C.C., Holt‐Martyn, J.P., Chowdhury, R., McDonough, M.A. and Schofield, C.J. (2021) Inhibition of JMJD6 by 2‐oxoglutarate Mimics. ChemMedChem, 17, e20210039. [Google Scholar] [CrossRef] [PubMed]
[48] Suvà, M.L. and Tirosh, I. (2020) The Glioma Stem Cell Model in the Era of Single-Cell Genomics. Cancer Cell, 37, 630-636. [Google Scholar] [CrossRef] [PubMed]
[49] Napier, K.J. (2014) Esophageal Cancer: A Review of Epidemiology, Pathogenesis, Staging Workup and Treatment Modalities. World Journal of Gastrointestinal Oncology, 6, 112-120. [Google Scholar] [CrossRef] [PubMed]
[50] Golyan, F.F., Druley, T.E. and Abbaszadegan, M.R. (2019) Whole-Exome Sequencing of Familial Esophageal Squamous Cell Carcinoma Identified Rare Pathogenic Variants in New Predisposition Genes. Clinical and Translational Oncology, 22, 681-693. [Google Scholar] [CrossRef] [PubMed]
[51] Liu, H., Jiang, M., Ma, F., Qin, J., Zhou, X., Xu, L., et al. (2023) JMJD6 Functions as an Oncogene and Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma. BMC Cancer, 23, Article No. 696. [Google Scholar] [CrossRef] [PubMed]
[52] Johnson, D.E., Burtness, B., Leemans, C.R., Lui, V.W.Y., Bauman, J.E. and Grandis, J.R. (2020) Head and Neck Squamous Cell Carcinoma. Nature Reviews Disease Primers, 6, Article No. 92. [Google Scholar] [CrossRef] [PubMed]
[53] Guo, B., Wang, L., Qin, X., Shen, Y. and Ma, C. (2019) Jumonji Domain-Containing Protein 6 Functions as a Marker of Head and Neck Squamous Cell Carcinoma at Advanced Stage with No Effect on Prognosis. Oncology Letters, 18, 5843-5852. [Google Scholar] [CrossRef] [PubMed]

为你推荐